Compare REA & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REA | CDXS |
|---|---|---|
| Founded | N/A | 2002 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Major Chemicals |
| Sector | Basic Materials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.9M | 256.3M |
| IPO Year | 2026 | 2008 |
| Metric | REA | CDXS |
|---|---|---|
| Price | $11.75 | $2.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 150.8K | ★ 871.3K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $7.73 |
| Revenue Next Year | N/A | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $11.80 | $0.96 |
| 52 Week High | $17.84 | $3.87 |
| Indicator | REA | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 16.75 | 56.15 |
| Support Level | N/A | $2.41 |
| Resistance Level | $16.18 | $2.73 |
| Average True Range (ATR) | 1.41 | 0.17 |
| MACD | -0.44 | 0.03 |
| Stochastic Oscillator | 6.16 | 84.62 |
Rare Earths Americas Inc is an exploration stage company focused on advancing projects related to rare earth minerals. Its activities include evaluating mineralization and assessing the characteristics and economic potential of its assets. Its portfolio includes the Shiloh Project in Georgia, United States; the Alpha Project in Bahia, Brazil; and the Constellation Project in Minas Gerais, Brazil. It also holds additional early-stage exploration projects, including the Homer Project in Goiás, Brazil, and the Liberty Peak Project in Georgia, United States. The company has two reportable segments due to their geographical location: United States Mining Operations and Brazil Mining Operations.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.